Abstract
Immunity to Human Immunodeficiency Virus (HIV) Infection
Highlights
The advent of highly active antiretroviral therapy (HAART) in 1996 revolutionized life expectancy and quality of life of people infected by HIV in the developed Countries
HIV-infected patients can positively think that their life expectancy is comparable to that of people of the same age and with the same pattern of risk factors there are clear demonstrations that mortality patterns in most nonintravenous drug users HIV infected individuals with high CD4+ T-cell counts restored by HAART are similar to those in the general population [1]
The main finding is that immune activation is hyperexpressed in patients with HIV-associated neurocognitive disorders (HANDs) and less sensitive to HAART than the HIV load in the cerebrospinal fluid (CSF)
Summary
The advent of highly active antiretroviral therapy (HAART) in 1996 revolutionized life expectancy and quality of life of people infected by HIV in the developed Countries. HIV-infected patients can positively think that their life expectancy is comparable to that of people of the same age and with the same pattern of risk factors there are clear demonstrations that mortality patterns in most nonintravenous drug users HIV infected individuals with high CD4+ T-cell counts restored by HAART are similar to those in the general population [1]. Not all HIV-infected patients on HAART are able to restore their CD4+ T-cell count, and signs of immune deficits or immune activation persist in most individuals despite an apparent control of HIV viremia and a mere increase of the CD4+ T-cell number.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
